Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts

US Consumer Sentiment Tops Estimates In January, Hits Highest Level Since July 2021: Friday’s Economic Digest
U.S. consumer confidence in January continues to exceed even the most optimistic expectations among analysts, reaching its highest levels in…
Crypto Analyst Says Bitcoin Could Reach All-time High In ‘Less Than Half A Year,’ Cites S&P 500’s Performance
Crypto analyst and trader Kevin Svenson recently shared his perspective on the potential future movements of Bitcoin (CRYPTO: BTC), drawing a comparison…